3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Childhood Brain Neoplasm
2
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Malignant Solid Neoplasm
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Interventions
Vincristine
25
Cyclophosphamide
25
Irinotecan
21
Temozolomide
18
Doxorubicin
16
Radiotherapy
15
Filgrastim
15
Ifosfamide
14
Dactinomycin
14
Etoposide
11
Vinorelbine
9
Melphalan
9
Magnetic Resonance Spectroscopy
9
Granulocyte Colony-Stimulating Factor
9
Radiation
8
pegfilgrastim
7
X-Rays
7
Specimen Handling
7
Sirolimus
7
Topotecan
6
Phantoms, Imaging
6
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
cixutumumab
5
Busulfan
5
Biopsy
5
temsirolimus
4
irinotecan sucrosofate
4
fludarabine
4
etoposide phosphate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rhabdomyosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts